as of 12-26-2025 3:43pm EST
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 628.9M | IPO Year: | 2025 |
| Target Price: | $39.33 | AVG Volume (30 days): | 189.2K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -40.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.88 - $24.03 | Next Earning Date: | 12-11-2025 |
| Revenue: | $13,000,000 | Revenue Growth: | 160.00% |
| Revenue Growth (this year): | 89.43% | Revenue Growth (next year): | N/A |
See how EVMN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EVMN Evommune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.